



2024

Annual Savings Report

CivicaScript was founded in 2020 to provide affordable generic and biosimilar medicines through “disruptive collaboration” with our members and manufacturing partners.

CivicaScript’s business is based on the health care utility model, defined as a “self-sustaining nonstock corporation with a social mission, formed by health care institutions to provide essential products and services at the lowest sustainable cost through a focused, transparent and scalable business model.”¹

CivicaScript launched generic abiraterone in 2022 as its first product, using the specialty drug as our proof of concept for this business model. In 2022-23, the company worked with our payer members to switch patients to CivicaScript abiraterone. This resulted in significant cost savings for patients (64%, or \$81/month), and payers (92%, or \$1,796/month) from September to December 2023 alone. The results of this proof-of-concept phase were published in May 2025 in *The New England Journal of Medicine Catalyst*.¹

This 2024 Annual Savings Report builds on those initial positive results by reporting the savings realized by CivicaScript payer members and patients in 2024. These new results continue to validate the success of our business model in delivering on our mission of making generic medicines and biosimilars available and affordable to everyone.

Total savings

2024 was a significant year for CivicaScript, as we continued to convert patients to CivicaScript abiraterone and prepare for 2025 launches of additional products.

With a full year of data now available, we saw continued savings for both CivicaScript members and patients – but also the opportunity for even more savings if more patients had switched to our product.


- Through use of CivicaScript abiraterone in 2024, CivicaScript payer members and patients saved a total of \$17.8M.
- If our members had converted all of their beneficiary patients who use abiraterone to CivicaScript abiraterone, an additional \$42.6M in savings could have been realized.



Patient savings


Patients who switched to CivicaScript abiraterone enjoyed significant savings in 2024, saving **64%** compared with those who used generic abiraterone from other manufacturers. This resulted in an average of **\$700** in savings per person over the course of 2024 — about \$60 per claim.

ANNUAL AVERAGE PATIENT COST



Out-of-pocket costs also were much more stable throughout the year for patients using CivicaScript abiraterone compared with generic abiraterone from other manufacturers, regardless of what stage of their health-insurance benefit patients were in. This provided both transparency and predictability in their pharmacy costs.

PATIENT SPEND OVER TIME FOR MONTH SUPPLY 120-COUNT BOTTLE



Payer savings

CivicaScript member payers also experienced significant savings in 2024 — a total of \$16.9M — by connecting patients with CivicaScript abiraterone.

On average, member payers saved 91% — about \$1,125 per claim — when patients switched to CivicaScript abiraterone. Based on these results, if all of their patients had converted to CivicaScript abiraterone in 2024, CivicaScript members would have realized an additional \$40.6M in savings, for a total of \$57.5M




Increased use,
decreased
costs – and the
sentinel effect

Although abiraterone use increased from 2023 to 2024, total abiraterone **spending decreased** for CivicaScript members.


CivicaScript payer members spent a total of \$51M on abiraterone in 2024, compared with \$59M in 2023 – a decrease of 13%. Yet CivicaScript member patients used 5.7M abiraterone tablets in 2024, compared with 4.6M tablets in 2023. The reduced payer spending reflects a full year of patient conversion to CivicaScript abiraterone, compared with a much shorter time frame the previous year.

TOTAL ABIRATERONE UTILIZATION VS. SPEND 2023-2024



Interestingly, the average cost of abiraterone from all other manufacturers declined between 2022 and 2024, decreasing 19% from 2023 to 2024. We believe this is a sentinel effect from CivicaScript abiraterone’s launch into the marketplace. Market impact is a key tenet of the CivicaScript mission, and we are proud to promote broader savings for all payers and patients by encouraging price competition.

AVERAGE MONTHLY CLAIM COST 2022-2024



More savings potential

CivicaScript provided substantial savings to our payer members and their patient beneficiaries in 2024 through our low-cost abiraterone — and contributed much-needed transparency to the marketplace.

However, a large number of patients have not yet switched to CivicaScript abiraterone — representing a significant opportunity to bring even more savings to payers and patients.

Ongoing challenges to patient conversion to CivicaScript abiraterone include pushback from large legacy pharmacy benefit managers. We will continue to work with our members to disrupt the current supply chain so that more patients will have access to our low-cost medicines and biosimilars.

Opportunity for growth also exists with our continuously growing portfolio. This year, our offerings expanded to include four additional products: droxidopa, dimethyl fumarate, dalfampridine and capecitabine. These new products provide the potential for major additional savings for patients and our payer members, and we look forward to reporting those results in 2026.

We also launched a proprietary name for our abiraterone product (Abirtega™) this year, an innovative approach that supports payers’ ability to guide patients to the low-cost product. Abirtega-branded product will fully replace our unbranded abiraterone once supplies of the latter are depleted. In line with the health care utility model, as use of CivicaScript abiraterone increased, we were able to secure a discount for abiraterone from the manufacturer. This allowed us to reduce the WAC price 25% to \$120 per 120-count bottle of Abirtega.

CIVICAScript PRODUCT LAUNCHES 2025	BRAND EQUIVALENT
Droxidopa	Northera
Dimethyl fumarate	Tecfidera
Dalfampridine	Ampyra
Capecitabine	Xeloda
Abirtega (abiraterone proprietary name)	Zytiga

Upcoming launches

Starting in January 2026, in partnership with Civica, Inc., CivicaScript will offer a low-cost insulin glargine biosimilar through private-label distribution. The new long-acting **insulin glargine-yfgn** will be interchangeable with Lantus. Civica continues to develop its own insulin program at its manufacturing facility in Petersburg, Va.

CivicaScript also has announced a partnership to distribute low-cost biosimilar **ustekinumab-aaaz** starting in January 2026. Ustekinumab-aaaz is our first biosimilar offering and is an interchangeable version of Stelara. Its launch is an important opportunity in the biosimilar marketplace to help ensure affordability for therapies with significant cost.

Looking ahead

The substantial savings for payers and patients generated by CivicaScript in 2024 underscore the power of collaboration, transparency and alignment on a shared mission to make medicines affordable and available to all who need them.

These savings validate the health care utility model and support CivicaScript's influence on broader market pricing.

Continued success will depend on removing barriers to adoption of our low-cost products and working with our member payers to convert more patients to our products.

As we further expand our portfolio, our focus remains on building a durable, collaborative framework that delivers lasting value to patients, payers and the broader healthcare system.

REFERENCES

- ¹. Dredge, C, Scholtes S. Changing the Script on Drug Pricing: A New Type of Supplier Creates Savings for Patients and Plans. *NEJM Catalyst*, June 2025.



For more information, please visit civicascript.com.